Did you mean aromatase inhibitor?
Displaying drugs 126 - 150 of 2437 in total
Stiripentol
Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. However, its clinical efficacy as...
Approved
Matched Categories: … BCRP/ABCG2 Inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors …
Ataluren
Ataluren is a novel, orally administered drug that targets nonsense mutations. Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. More specifically, ataluren is used in the small group of patients whose...
Approved
Investigational
Matched Categories: … OATP1B3 inhibitors ... OAT1/SLC22A6 inhibitors ... OAT3/SLC22A8 Inhibitors …
Fusidic acid
An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... BCRP/ABCG2 Inhibitors ... BSEP/ABCB11 Inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Protein Synthesis Inhibitors …
Roxithromycin
Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is...
Approved
Investigational
Withdrawn
Matched Categories: … OATP1B3 inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors …
Gemifloxacin
Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Topoisomerase Inhibitors ... Topoisomerase II Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …
Luliconazole
Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.
Approved
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors (weak) …
Quinupristin
Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. The combination of the two components acts synergistically and is more...
Approved
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (weak) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Entacapone
Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of...
Approved
Investigational
Matched Categories: … COMT Inhibitors ... Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors (weak) …
Hydroxyurea
Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea...
Approved
Matched Categories: … Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Nucleic Acid Synthesis Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Indapamide
The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a number of lifestyle changes (ie. reduced...
Approved
Matched Description: … tool for the treatment of hypertension and continue to grow in popularity, falling behind only ACE inhibitors …
Matched Categories: … Sodium Chloride Symporter Inhibitors …
Matched Categories: … Sodium Chloride Symporter Inhibitors …
Amiodarone
Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone...
Approved
Investigational
Matched Categories: … OCT2 Inhibitors ... BSEP/ABCB11 Inhibitors ... Enzyme Inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors …
Nalidixic acid
Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... OAT1/SLC22A6 inhibitors ... Topoisomerase Inhibitors ... Topoisomerase II Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors …
Enoxacin
A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Topoisomerase Inhibitors ... Topoisomerase II Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …
Moxifloxacin
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Topoisomerase Inhibitors ... Topoisomerase II Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …
Lomustine
An alkylating agent of value against both hematologic malignancies and solid tumors.
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors (weak) …
Dosulepin
Dosulepin (INN, BAN) formerly known as dothiepin (USAN), is a tricyclic antidepressant with anxiolytic properties that is used in several European and South Asian countries, as well as Australia, South Africa, and New Zealand. It is not FDA-approved due to low therpeutic index and significant toxicity in overdose. Dosulepin inhibits...
Approved
Matched Categories: … Adrenergic Uptake Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors …
Antithrombin Alfa
Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations.
Approved
Investigational
Matched Categories: … Factor Xa Inhibitors ... Thrombin Inhibitors …
Edetate disodium anhydrous
Edetate disodium anhydrous is a polyvalent chelating agent used to treat hypercalcemia and digitalis toxicity associated ventricular arrhythmias.
Approved
Vet approved
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Alatrofloxacin
Alatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It was withdrawn from the U.S. market in 2001.
Approved
Withdrawn
Matched Categories: … Enzyme Inhibitors ... Topoisomerase Inhibitors ... Topoisomerase II Inhibitors …
Nicardipine
A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors …
Fluoxetine
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
Approved
Vet approved
Matched Categories: … Enzyme Inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Noscapine
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Istradefylline
Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A2A receptors in the basal ganglia. This region of the brain is highly involved in motor control. Istradefylline...
Approved
Investigational
Matched Categories: … MATE inhibitors ... BCRP/ABCG2 Inhibitors ... MATE 1 Inhibitors ... MATE 2 Inhibitors ... OATP1B3 inhibitors …
Peramivir
Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Neuraminidase Inhibitors ... Neuraminidase, antagonists & inhibitors …
Cerivastatin
On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.[A669,L43942]
Approved
Withdrawn
Matched Categories: … Enzyme Inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Displaying drugs 126 - 150 of 2437 in total